S6 Table lists the number of CTCF-mutations for each cancer type and shows that the highest mutation rates at functional CTCF sites per individual are suffered by liver and lung tumours, with substantial mutational loads also seen for breast, pancreas and lymphoma samples. In contrast, the relatively numerous (Table 1) medulloblastoma and astrocytoma samples show orders of magnitude lower rates per individual, suggesting that different cancer types experience very different degrees of CTCF binding site disruption (S6 Table). This evidence concerns the gene CTCF and lymphoma.